Trials / Completed
CompletedNCT06099067
Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)
Harmonizing RCT-Duplicate Emulations: A Real World Replication Program Analyzing Three Clinical Trials, CANVAS, LEADER, and SAVOR TIMI in Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 239,990 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Replication of three clinical trial emulations CANVAS, LEADER, and SAVOR TIMI that form part of the RCT-Duplicate initiative, sponsored by the FDA and delivered by the Brigham and Women's Hospital and Harvard Medical School. AstraZeneca will use the Instant Health Data platform PANALGOS (IHD) for the analyses.
Detailed description
RCT-duplicate (RCT-D) is an initiative led by the Brigham and Women's Hospital and Harvard Medical School, that selected 30 clinical trials as part of an empirical experiment where these trials would be emulated using RWD. AstraZeneca will replicate three emulations CANVAS, LEADER, and SAVOR TIMI from among the 30 plus clinical trials analyzed in RCT-D. These clinical trials assess type 2 diabetes mellitus drugs. The replications will be conducted on the Instant Health Data PANALGOS (IHD) platform to assess these studies in two claims databases Optum and IBM Watson Market Scan. The aim is to recreate these three emulations to investigate the reproducibility of the emulations, increase transparency and better understand the process of trial emulations; and where possible, contribute with potential improvements to the RCT-D framework.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Canagliflozin | Canagliflozin dispensing claim is used as the exposure drug in CANVAS replication |
| DRUG | DPP4 inhibitor | DPP4 inhibitor dispensing claim is used as the reference drug in CANVAS and LEADER replications |
| DRUG | Liraglutide | Liraglutide dispensing claim is used as the Exposure drug in LEADER replication |
| DRUG | Saxagliptin | Saxagliptin dispensing claim is used as the Exposure drug in SAVOR-TIMI replication |
| DRUG | 2nd generation Sulfonylurea | 2nd generation Sulfonylurea dispensing claim is used as the Exposure drug in SAVOR-TIMI replication |
Timeline
- Start date
- 2020-05-15
- Primary completion
- 2023-08-31
- Completion
- 2023-08-31
- First posted
- 2023-10-25
- Last updated
- 2024-08-30
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT06099067. Inclusion in this directory is not an endorsement.